Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AML-VAC multi-peptide vaccine + XS15
- Development stage
- Unknown
- Lead developer
- Universitätsklinikum Tübingen
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
AML-VAC multi-peptide vaccine + XS15 is an investigational therapeutic cancer vaccine combination developed by the University Hospital of Tübingen. It is designed for patients with acute myeloid leukemia (AML) who have achieved complete remission after first-line therapy. The vaccine consists of a cocktail of multiple HLA-restricted peptides derived from leukemia-associated antigens (LAAs) and is adjuvanted with XS15, a novel water-soluble Toll-like receptor 1/2 (TLR1/2) ligand. XS15 (Pam3Cys-GDPKHPKSF) acts as a potent immunostimulant that promotes the maturation of antigen-presenting cells and induces a strong Th1-polarized T-cell response. The primary goal of this treatment is to eliminate minimal residual disease (MRD) and prevent disease relapse by stimulating the patient's immune system to recognize and destroy remaining leukemic cells.
- Other names
- AML-VAC-XS15AML-VAC-XS-15AML-VAC-XS 15AML-VAC multi-peptide vaccine with XS15AML-VAC + XS15
02
Targets
Acute myeloid leukemia-associated human leukocyte antigen-presented peptide antigensTLR1
Beyond the preview
Go deeper on AML-VAC multi-peptide vaccine + XS15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AML-VAC multi-peptide vaccine + XS15.